| Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice LA Gallo, MS Ward, AK Fotheringham, A Zhuang, DJ Borg, NB Flemming, ... Scientific reports 6 (1), 26428, 2016 | 162 | 2016 |
| Mitochondrial dysfunction and signaling in diabetic kidney disease: oxidative stress and beyond NB Flemming, LA Gallo, JM Forbes Seminars in nephrology 38 (2), 101-110, 2018 | 81 | 2018 |
| Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes MS Ward, NB Flemming, LA Gallo, AK Fotheringham, DA McCarthy, ... Scientific Reports 7 (1), 15190, 2017 | 39 | 2017 |
| Stably engineered nanobubbles and ultrasound-An effective platform for enhanced macromolecular delivery to representative cells of the retina SS Thakur, MS Ward, A Popat, NB Flemming, MO Parat, NL Barnett, ... PloS one 12 (5), e0178305, 2017 | 35 | 2017 |
| Tapping into mitochondria to find novel targets for diabetes complications N B Flemming, L A Gallo, M S Ward, J M Forbes Current drug targets 17 (12), 1341-1349, 2016 | 30 | 2016 |
| Soluble RAGE prevents type 1 diabetes expanding functional regulatory T cells SS Leung, DJ Borg, DA McCarthy, TE Boursalian, J Cracraft, A Zhuang, ... Diabetes 71 (9), 1994-2008, 2022 | 13 | 2022 |
| Mitochondrial dysfunction in individuals with diabetic kidney disease: a systematic review N Flemming, L Pernoud, J Forbes, L Gallo Cells 11 (16), 2481, 2022 | 10 | 2022 |
| T-cell expression and release of kidney injury molecule-1 in response to glucose variations initiates kidney injury in early diabetes JM Forbes, DA McCarthy, AJ Kassianos, T Baskerville, AK Fotheringham, ... Diabetes 70 (8), 1754-1766, 2021 | 10 | 2021 |
| Between-day reliability of cytokines and adipokines for application in research and practice GL Rose, MJ Farley, NB Flemming, TL Skinner, MA Schaumberg Frontiers in Physiology 13, 967169, 2022 | 4 | 2022 |
| Expansion of Functional Regulatory T Cells Using Soluble RAGE Prevents Type 1 Diabetes SS Leung, DJ Borg, DA McCarthy, TE Boursalian, J Cracraft, A Zhuang, ... bioRxiv, 2020.01. 10.902627, 2020 | 1 | 2020 |
| YOUTH WITH TYPE 1 DIABETES AT HIGHER RISK OF DEVELOPING DIABETIC KIDNEY DISEASE HAVE ALTERATIONS IN THEIR URINE AND PLASMA METABOLOMIC AND MITOCHONDRIAL DNA PROFILES M Sullivan, U Pham, D McCarthy, N Flemming, A Fotheringham, ... Nephrology 28, 28-29, 2023 | | 2023 |
| Mitochondrial dysfunction aligns with risk for diabetic kidney disease in youth with type 1 diabetes M Sullivan, D Mccarthy, N Flemming, P Chandrashekar, M Hodson, ... Nephrology 27 (Supplement 1), 32-33, 2022 | | 2022 |
| Mitochondrial Dysfunction in Individuals with Diabetic Kidney Disease: A Systematic Review. Cells 2022, 11, 2481 N Flemming, L Pernoud, J Forbes, L Gallo s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2022 | | 2022 |
| Mitochondrial dysfunction as a pathological mediator in diabetic kidney disease N Flemming | | 2021 |
| Mitochondrial dysfunction defines a population of young people with type 1 diabetes at risk of kidney disease JM Forbes, NB Flemming, DA Mccarthy, K Boot, N De Silva, LA Gallo, ... Nephrology 22, 29-30, 2017 | | 2017 |
| Ultrasound-responsive nanobubbles for enhanced posterior eye drug delivery S Thakur, MO Parat, NL Barnett, MJ Ward, N Flemming, A Popat, ... 42nd Annual Meeting & Exposition of the Controlled Release Society, 2015 | | 2015 |
| Mitochondrial targeting of superoxide by Mitoq improves metabolic renal dysfunction MS Ward, NB Flemming, LA Gallo, A Fotheringham, G Gobe, D Vesey, ... Nephrology 19 (S4), 56-56, 2014 | | 2014 |
